- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05473468
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
November 1, 2022 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Single Center, Single Dose, Open Label Phase 1 Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance And Metabolism Of [14c]-Famitinib In Healthy Adult Male Subjects
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Shanghai Xuhui District Central Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy adult male between the ages of 18 and 45 years;
- Total body weight ≥ 50 kg, and the Body Mass Index (BMI) of 19 to 28 kg/m2;
- Male subjects of childbearing potential and their partners have no birth or sperm donation plan and voluntarily take effective contraception during the course of clinical trial until 6 months after the drug administration;
- An informed consent document signed and dated by the subject;
- Normal bowel movements (1 to 2 times a day), no habitual constipation or diarrhea.
Exclusion Criteria:
- No clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests;
- Positive results of hepatitis B surface antigen, hepatitis C antibody, HIV antibody or treponema pallidum antibody;
- Have taken any clinical trial drug or participated in any clinical trial within 3 months before administration;
- CYP3A4 inducers or inhibitors were taken within 28 days before administration;
- Have taken any prescription or over-the-counter drugs, vitamin products, health care drugs, traditional Chinese medicines or food supplements within 14 days before administration;
- Those who need to receive anticoagulant therapy such as warfarin or thrombin inhibitors and/or aspirin antiplatelet therapy within 1 month before administration and during the study period;
- There are clinically significant bleeding symptoms or clear bleeding tendencies within 3 months before administration, such as gastrointestinal bleeding and peptic ulcers;
- History of stroke or intracranial hemorrhage within 6 months before administration;
- Have uncontrolled clinical symptoms or diseases of the heart, such as: (1) heart failure above NYHA2 (2) unstable angina (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) screening period QTcF >450 ms (male);
- Those who have undergone major surgery within 6 months before administration or that surgical incision has not completely healed; Major surgery includes, but is not limited to, any surgery that is at significant risk of bleeding, prolongs the period of general anesthesia, or has an incision biopsy or significant traumatic injury;
- Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before administration;
- Hemorrhoids or perianal diseases accompanied by regular / hematochezia; Those with gastrointestinal abnormalities such as irritable bowel syndrome and inflammatory bowel disease, which may affect drug absorption as determined by investigator;
- People with allergic constitution or allergic diseases, including those with severe drug allergies or history of drug allergies, and those who are known to be allergic to famitinib or excipients;
- Have any history of clinical serious diseases or diseases or conditions that the researcher believes may affect the results of the trial, including but not limited to circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, psychiatric and metabolic disease history; Lifestyle Habits;
- History of alcoholism with alcohol consumption over 14 units per week;; and can't abstain from smoking and alcohol during the study;
- Heavy smoker or habitually use nicotine-containing products;
- Have a history of drug abuse or have used soft drugs (such as: marijuana) within 3 months before administration or take drugs (such as cocaine, amphetamines, phencyclidine, etc.) within 1 year before administration; or positive urine drug abuse test during screening periods;
- Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeinated beverages (more than 8 cups a day, 1 cup = 250 mL) and unable to quit during the study period;
- Those who cannot tolerate venipuncture or with a history of needle-sickness and blood-sickness;
- Workers who require long-term exposure to radioactive conditions; or those who have significant radiation exposure (≥ 2 chest/abdominal CT scans, or 3 other X-ray tests ≥) within 1 year prior to administration or who have participated in radiopharmaceutical labeling tests;
- Blood donation no less than 400 mL or have blood transfusion within 3 months of dosing;
- Subjects who, in the opinion of the Investigator should not participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment group
|
a single oral dose of [14C]famitinib (25 mg/150 uCi suspension)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mass balance recovery of total radioactivity in all excreta urine: CumAe and Cum%Ae
Time Frame: 0-336 hours
|
Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the urine from time t1 to time t2
|
0-336 hours
|
Mass balance recovery of total radioactivity in all excreta feces: CumAe and Cum%Ae
Time Frame: 0-336 hours
|
Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the feces from time t1 to time t2
|
0-336 hours
|
Total recovery of radioactivity in urine and feces as percentage of total radioactive dose administered
Time Frame: 0-336 hours
|
To characterize the extent of excretion of total radioactivity in urine and feces following administration of famitinib
|
0-336 hours
|
Metabolic Profiling in Blood
Time Frame: 0 to 240 hours
|
Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in plasma if possible.
|
0 to 240 hours
|
Metabolic Profiling in Urine
Time Frame: 0-336 hours
|
Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in urine if possible.
|
0-336 hours
|
Metabolic Profiling in Feces
Time Frame: 0-336 hours
|
Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in feces if possible.
|
0-336 hours
|
Ratio of radioactivity of whole blood and plasma blood
Time Frame: 0-72 hours
|
0-72 hours
|
|
Radioactivity AUC
Time Frame: 0-240 hours
|
0-240 hours
|
|
Plasma famitinib and SHR116637: AUC
Time Frame: 0-240 hours
|
0-240 hours
|
|
Plasma famitinib and SHR116637: Cmax
Time Frame: 0-240 hours
|
0-240 hours
|
|
Plasma famitinib and SHR116637: Tmax
Time Frame: 0-240 hours
|
0-240 hours
|
|
Radioactivity Tmax
Time Frame: 0-240 hours
|
0-240 hours
|
|
Radioactivity Cmax
Time Frame: 0-240 hours
|
0-240 hours
|
|
Plasma famitinib and SHR116637: t1/2
Time Frame: 0-240 hours
|
0-240 hours
|
|
Radioactivity t1/2
Time Frame: 0-240 hours
|
0-240 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AEs and SAEs
Time Frame: 0-14 days
|
0-14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 26, 2022
Primary Completion (ANTICIPATED)
November 1, 2022
Study Completion (ANTICIPATED)
November 1, 2022
Study Registration Dates
First Submitted
July 20, 2022
First Submitted That Met QC Criteria
July 25, 2022
First Posted (ACTUAL)
July 26, 2022
Study Record Updates
Last Update Posted (ACTUAL)
November 2, 2022
Last Update Submitted That Met QC Criteria
November 1, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- FMTN-I-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsRecruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Famitinib
-
Jiangsu HengRui Medicine Co., Ltd.CompletedColorectal Cancer Metastatic | Colorectal Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, ChinaSuspendedNon-Small Cell Lung Cancer (NSCLC)China
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRenal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen UniversityCompletedRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownGastrointestinal Stromal TumorChina
-
Shanghai Chest HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesTerminatedGastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting